MOUNTAIN VIEW, Calif., Oct. 14, 2011 /PRNewswire/ -- VIVUS, Inc. (NASDAQ: VVUS) today announced that Timothy Morris, chief financial officer, will present an overview of the company at the 2011 BioCentury NewsMakers in the Biotech Industry Conference.
The VIVUS presentation will take place at the Millennium Broadway Hotel in New York, NY on Friday, October 21, 2011 at 10:00 a.m. ET. A live webcast and 30-day archive of the presentation will be available at http://ir.vivus.com.
About VIVUS
VIVUS is a biopharmaceutical company developing therapies to address obesity, sleep apnea, diabetes and male sexual health. The company's lead investigational product in clinical development, QNEXA®, has completed phase 3 clinical trials for the treatment of obesity and is currently being considered for approval by US and EU regulators. VIVUS received a Complete Response Letter, or CRL, to the initial QNEXA NDA on October 28, 2010. QNEXA is also in phase 2 clinical development for the treatment of type 2 diabetes and obstructive sleep apnea. In the area of sexual health, VIVUS has submitted an NDA for avanafil, a PDE5 inhibitor being studied for the treatment of erectile dysfunction. For more information about the company, please visit www.vivus.com.
CONTACT: | |||
VIVUS, Inc. | Investor Relations: | The Trout Group | |
Timothy E. Morris | Brian Korb | ||
Chief Financial Officer | |||
650-934-5200 | 646-378-2923 | ||
SOURCE VIVUS, Inc.
